Delivery Order SPE2DB24D2205-SPE2DB25FDXHT

Award Date 1/24/25
Potential Completion Date 1/27/25
Potential Value $7.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The federal contract award is for the pharmaceutical product MOUNJARO 5 MG/0.5 ML PEN 0.5ML, awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $41,031.57 firm fixed-price delivery order contract has a completion date of December 9, 2024. This award is part of AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC provides a...
This federal contract award from the Defense Logistics Agency (DLA) is for the procurement of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, as a delivery order under an existing Indefinite Delivery Contract (IDC) valued at $999,999,999 with DLA Troop Support Medical. This IDC serves as a primary vehicle for the company to provide a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,913.02, is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,145.73, is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a comprehensive...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,710.66, is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,052 firm fixed-price delivery order is for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product, with an ultimate completion date of October 22, 2024. The contract has no set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award is for the delivery of the pharmaceutical product MOUNJARO 5 MG/0.5 ML PEN 0.5ML to the Defense Logistics Agency (DLA). The $4,991.94 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on November 12, 2024, with a completion date of November 13, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award is for the pharmaceutical product MOUNJARO 5 MG/0.5 ML PEN 0.5ML, awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $5,260.00 firm fixed price delivery order has a completion date of September 23, 2024. It is not designated as a set-aside contract. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The $14,403.58 firm fixed-price contract has a completion date of March 14, 2023. The award is not associated with a set-aside program. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary...
This federal contract award, valued at $11,075.71, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of MOUNJARO 5 MG/0.5 ML PEN 0.5ML, a medical product, with a completion date of July 10, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
  • SPE2DB24D2205
    Indefinite Delivery Contract
  • SPE2DB24D2205-SPE2DB25FDXHT
    Delivery Order

This federal contract award from the Defense Logistics Agency (DLA) is for the pharmaceutical product MOUNJARO 5 MG/0.5 ML PEN 0.5ML. The contract, valued at $7,898.76, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This is a delivery order under AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has a performance period through January 27, 2025 and utilizes a Firm Fixed Price pricing type. The contract award does not specify any set-aside requirements, indicating open competition.

Generated 4/25/25, 10:07 AM